Business
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 18, 2019\n\n\n\nTSX: IN OTCQX: IMLFF\n VANCOUVER, March 18, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today announced the publication of the first in a series of pending patent applications directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.\n\n \n \n\n \nInternational Patent Application No. PCT/CA2018/051074, which recently published as WO2019046941, entitled 'METABOLIC ENGINEERING OF E. COLI FOR THE BIOSYNTHESIS OF CANNABINOID PRODUCTS', addresses the enablement and maximization of cannabinoid production through optimization of the precursor substrates needed to support specific cannabinoid synthesis.  This application, as well as two more recently-filed U.S. provisional patent applications, also cover various elements required to enable functional cannabinoid synthase production in an E. coli system.  The Company will actively seek to convert these two follow-on provisional applications, and subsequent provisional patents from new patent families, into additional Patent Cooperation Treaty (\"PCT\") applications in all major commercial jurisdictions, in due course.\nEric Hsu, PhD, InMed's Senior Vice President, Preclinical Research and Development, stated, \"The publication of our initial patent and the filing of two additional provisional patent applications supports InMed's continued expansion of intellectual property coverage for our proprietary biosynthesis program.  InMed will continue to position itself at the forefront of this and other innovative technologies to enable the manufacturing of pharmaceutical grade ...